Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talampanel in ALS
NCT00696332Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2008
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of talampanel in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change in ALS Functional Rating Score (ALSFRS-R slope) at 52 weeks. Started Sep 2008; status: completed.
02
Drugs
talampanel
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00696332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00696332.